Ascendis Pharma (ASND) Announces Proposed $500M ADS Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Ascendis Pharma (ASND) Prices 4.225M ADS Offering at $14/ADS
July 8, 2020 6:01 AM EDTAscendis Pharma A/S (NASDAQ: ASND) today announced the pricing of its underwritten public offering of 4,225,352 American Depositary Shares (ADSs), each of which represents one ordinary share of Ascendis, at a price to the public of $142.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about July 10, 2020 subject to customary closing conditions. In addition,... More
Ascendis Pharma (ASND) Receives Positive Opinion from Paediatric Committee of the European Medicines Agency on Agreement of Paediatric Investigation Plan
July 6, 2020 9:25 AM EDTAscendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that it received a positive opinion from the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) on its agreement with the proposed Paediatric Investigation Plan (PIP) for TransCon hGH (lonapegsomatropin), an investigational long-acting once-weekly prodrug of somatropin (human growth hormone or hGH) in development for treatment of growth hormone deficiency (GHD). The positive opinion is based on the non-clinical safety program, as well as data from the three phase 3 clinical... More
